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A 70-year-old man was referred to the hypertension clinic at the
Beilinson Medical Center by his family physician for evaluation and
treatment of resistant high blood pressure. He had had a cholecystecto-
my for gallstones some 30 years before and a prostatectomy 6 years
previously for benign hypertrophy. Blood pressure readings prior to the
prostatectomy were normal but rose to approximately 190/115 mm Hg
over the ensuing few years. During this interval, physical examination
revealed a mid-systolic murmur over the aortic area and a fourth
cardiac sound. Grade I—Il hypertensive retinopathy also was present.
An electrocardiogram revealed sinus rhythm and nonspecific T-wave
changes without evidence of left ventricular hypertrophy. Chest x-ray
disclosed slight dilation of the ascending aorta and mild enlargement of
the left ventricular shadow. Laboratory tests done 3 months before
admission revealed: erythrocyte sedimentation rate, 15 mm per hour;
hemoglobin, 16 g/dl; leukocytes, 8000/mm3 with a normal differential
count; BUN, 45 mg/dl; creatinine, 1.0 mg/dl; uric acid, 8.5 mgldt;
fasting blood glucose, 105 mgldl; cholesterol, 322 mg/dl; triglycerides,
173 mg/dl; and total lipids, 779 mg/dl. The urine sediment contained
waxy casts but otherwise was unremarkable. Urinary protein excretion
was 300 mg/day.
The patient was treated with hydrochlorothiazide, 50 mg daily for 24
months, but his hypertension did not improve. Alpha-methyldopa, 250
mg four times daily, was added for the next 6 weeks and was increased
to 500 mg four times daily for the subsequent 6 weeks. Symptomatic
orthostatic hypotension occurred but supine blood pressure levels
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remained elevated. Treatment therefore was changed to 160 mg of
propranolol and 50 mg of hydrochlorothiazide daily for several months
but was not successful in lowering blood pressure; a suspicion of patient
noncompliance was raised. However, severe shortness of breath devel-
oped during this period and resolved when propranolol administration
was discontinued.
During the year prior to referral, the patient received .450 mg of
clonidine and 50mg of hydralazine daily, and 50mg of hydrochlorothia-
zide every other day. Repeated blood pressure measurements remained
around 190/115 mm Hg. The serum creatinine increased to 2.5 mg/dl and
the BUN rose to 60 mg/dl. The patient complained of vertigo, fatigue,
dry mouth, and drowsiness. He refused to continue taking medication.
On physical examination, the blood pressure, measured in both arms
in the sitting and supine positions, was consistently in the range of 190/
115 mm Hg; the heart rate was 84 beats/mm. There was a systolic
murmur over the left carotid artery, and the left tibialis posterior and
dorsalis pedis arterial pulses were absent. Funduscopic examination
was unchanged. Electrocardiography, blood chemistries, and hemato-
logic studies also were unchanged. An isotope renal study showed
slightly reduced kidney size with no bladder residual.
All medications were stopped. Two weeks later the blood pressure
readings were unchanged. Simultaneous intraarterial and sphygmo-
manometric blood pressures were determined. The actual intraarterial
blood pressure was 160/90 mm Hg; systolic and diastolic values were
both 25 to 30 mm Hg less than those obtained by indirect measurement.
The patient was referred back to his family doctor with the recommen-
dation that antihypertensive medications be withheld.
Discussion
DR. JOSEPH B. ROSENFELD (Head, Department Internal
Medicine C, and the Renal Unit, Tel Aviv University Medical
School, Beilinson Medical Center, Petach Tikva, Israel): This
patient illustrates well some of the problems that physicians
face when caring for elderly hypertensive patients. In this
discussion, I arbitrarily will define individuals 65 years of age
and over as elderly. I will classify patients as hypertensive if the
systolic blood pressure is 160mm Hg or above or if the diastolic
blood pressure is 95 mm Hg or higher.
The population of older people is increasing rapidly in
developed countries. Some observers have projected that in the
United States the number of elderly will grow from 23 million to
55 million by the year 2050. The same trend is occurring in
Israel and in other Western countries. It is estimated that
physicians will spend as much as 75% of their time treating
elderly patients who have hypertension and cardiovascular
disease. Currently in Israel, patients over 65 years of age
account for more than 60% of all hospital beds used and they
consume a substantial part of the country's total health expen-
diture. Prevention of morbidity with more rational treatment of
common illnesses in this age group represents the single largest
opportunity for us to improve health care and reduce the
steadily increasing health budget.
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Epidemiology
Data collected by the National Health Survey in the United
States from 1960 to 1962 and from 1971 to 1974 reveal that
hypertension affects approximately 16% of the general popula-
tion [1]. The prevalence increases to about 50% in people over
age 65. Studies by Modan et al [2] and Medalie and colleagues
[3] have shown that the prevalence of hypertension in Israel
approximates that reported in the United States and many
European countries. The Framingham study suggested that
high blood pressure in adults is the main risk factor for stroke,
coronary disease, and congestive heart failure, especially in
those over 45 years old [4]. Hypertension was the primary risk
factor not only for mortality, but also for morbidity and
disability. Stroke is two to three times more common in elderly
hypertensives than in age-matched normotensive individuals
[5]. Senile dementia also is thought to be causally related to
hypertension [7].
Clinical research has disclosed more specific correlates be-
tween the measured blood pressure and end-organ damage,
morbidity, and mortality. More than 20 years ago, a study by
the Chicago Society of Actuaries showed that mortality from
cardiovascular disease correlated better with increases in sys-
tolic pressure than with increases in diastolic pressure [6]. More
recently, Colandrea et al showed that elderly patients with
persistent systolic hypertension had a morbidity and mortality
rate twice as great as that of normotensive individuals [7]. In the
Chicago People's Gas Company Study, individuals with isolat-
ed systolic hypertension had 1.9 times the mortality from
cardiovascular and renal diseases, and 3 times the mortality
from coronary heart disease [8]. This study focused on younger
individuals, however, and might not be relevant for patients
over 65 years of age.
The Framingham study revealed that the risk of all forms of
coronary disease and stroke in 18 years of follow-up was about
1 in 10 in individuals with normal systolic pressures, and was 1
in 3 in those with systolic pressures above 195 mm Hg [9]. Even
a slight elevation of systolic blood pressure is associated with a
likelihood of coronary disease 50% greater than the standard
risk [9]. Hypertension precedes congestive heart failure in 75%
of patients and congestive heart failure develops six times more
often in hypertensive patients than in normotensive individuals
[10]. Finally, at autopsy, heart weight and left ventricular
hypertrophy correlate better with systolic than with diastolic
blood pressure [10].
The accumulated data clearly point out that the elderly
hypertensive patient is at great risk: the older the age and the
higher the blood pressure, the greater the danger for significant
morbid events. In fact, more than 50%, of the hypertensive
patients with congestive heart failure are dead in 5 years [10],
and only one of 5 patients in the elderly age group makes a
good, functional recovery after a severe stroke [10].
Physiologic considerations in the older patient
What makes the elderly so vulnerable? A brief review of the
physiologic changes that affect the various organ functions and
homeostatic systems in the elderly should provide the answer.
Studies of Western society show, contrary to general belief,
that blood pressure does not automatically rise with age [11]. In
many parts of the world, for example Africa and Oceania, and
even in many older people in Western society, arterial blood
pressure remains below 160/95 mm Hg despite aging.
The cardiovascular system. Cardiac output is reduced in the
elderly because of reduced myocardial contractility and de-
creased blood volume [12]. In the patient with mild, isolated
systolic hypertension, blood volume and cardiac output are
slightly reduced or normal, and total peripheral resistance is
moderately increased [13], but the compliant (SBP/SF) portion
of impedance to the left ventricular ejection is disproportion-
ately increased in comparison with the total peripheral resist-
ance. Peripheral resistance increases as a result of structural
changes in the vessels. To compensate, blood pressure in-
creases; this rise, as shown in puppies, is an expression of a
hemodynamic phenomenon characterizing normal growth and
development [14]. With time, elastic fibers of the media prolif-
erate; collagen, calcium, and cholesterol deposits increase; and
arterioles, the aorta, and some large arteries become rigid, thus
preventing dampening of the arterial pressure generated by the
stroke volume during left ventricular contraction. The in-
creased pressure in the peripheral arteries augments the me-
chanical stress that these vessels must oppose and eventually
this pressure causes an acceleration of atherosclerosis [15].
Precapillary arterioles are not protected, and increase of the
wall-to-lumen ratio of these arterioles aggravates the increase in
blood pressure. As a result, these vessels become more respon-
sive to vasoconstrictor and vasodilator agents and to nervous
and humoral stimuli [16].
Renal and electrolyte changes. Aging causes a 15% decrease
in renal cortical mass [17], a reduction in the number of
functioning glomeruli and tubules, and a consequent reduction
in GFR [18]. Benign nephrosclerosis damages the kidney,
especially if hypertension develops early. Because of the
decreased capacity and distensibility of the arterial tree, the
volume-pressure relationship shifts to the left; small changes in
volume cause abnormally large changes in arterial pressure,
especially in the patient with systolic hypertension. This is one
reason that elderly hypertensives are so sensitive to antihyper-
tensive drugs. The effect of salt consumption on blood pressure
in the elderly has not been clinically defined [19].
The renin-angiotensin-aldosterone system. Plasma renin ac-
tivity, angiotensin levels, and aldosterone secretion all decrease
with age in hypertensive as well as in normotensive individuals
[20]. Nephrosclerosis and a tendency for sodium retention have
been suggested as possible explanations [21, 22]. In addition, by
studying the relationship between age and the ability of pro-
pranolol to block the chronotropic effects of isoproterenol,
Vestal et al found that the effectiveness of any given free
concentration of propranolol and isoproterenol diminished pro-
gressively with age [23]. These data are compatible with a
diminished responsiveness of the f3-adrenoceptor to both ago-
nist and antagonist drugs. Accordingly, the depressed renin-
angiotensin-aldosterone system in the elderly can be explained
by a combination of factors including sodium retention, volume
expansion, decreased number of f3-receptors, and their respon-
siveness to agonists and suppressed renal renin release caused
by the increased perfusion pressure.
The nervous system. Cardiovascular responses to stress,
mediated via the sympathetic nervous system, are diminished in
the elderly. Plasma norepinephrine levels progressively in-
crease with advancing age in normotensive as well as in
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Fig. 1. Direct (open circles) and indirect (closed circles) systolic and
diastolic blood pressure measurements in 24 elderly patients (mean of5
measurements).
hypertensive individuals [24, 251. The hypertensive patient
displays a decreased sensitivity to the increased circulating
norepinephrine. This probably represents a compensatory re-
sponse to the decreased number of beta adrenoreceptors [231.
Atherosclerotic changes of the carotid sinus, rigidity of the
aorta, and reduced sensitivity of the baroreceptor area cause
dampening of the baroreceptor reflex. Thus, increase in blood
pressure is not associated with bradycardia and vasodilation. In
addition, compensatory tachycardia and vasoconstriction, fol-
lowing a decrease in blood pressure, are even more impaired
because of concomitant reduced vascular sensitivity to circulat-
ing catecholamines. As just noted, renin release also is impaired
in the aged. Thus a key compensatory mechanism, secondary
hyperreninemia, which is essential for optimal maintenance of
arterial pressure, is seriously impaired.
In patients with systolic hypertension, the indices of ventric-
ular ejection are within normal limits. Arterial compliance,
however, is significantly reduced and correlates negatively with
the level of systolic pressure [26]. These neural, hormonal, and
hemodynamic changes underscore the need to take great care in
planning therapy for the elderly patient with hypertension.
Evaluating hypertension in the older patient
Hypertension in the elderly can be classified into three main
types: (1) isolated systolic hypertension, in which diastolic
blood pressure is normal or low; (2) predominant systolic
10 Controls
Fig. 2. Direct (open circles) and indirect (closed circles) systolic and
diastolic blood pressure measurements in 10 control subjects (mean of 5
measurements).
hypertension, in which both the systolic and diastolic pressures
are increased, but in which the pulse pressure is markedly
increased; and (3) combined systolic and diastolic hyperten-
sion, in which the systolic and diastolic pressures are increased
and the pulse pressure is normal.
When examining an elderly patient, one should first measure
blood pressure in both arms, with the patient in the supine and
seated positions, then measure blood pressure 2 to 5 minutes
later with the patient standing. Caird, Andrews, and Kennedy
reported that one minute of quiet standing in 494 persons aged
65 years or more, of whom only 30% received drugs, decreased
systolic pressure 20 mm Hg or more in 24% [27]. In 9% the
decrease was 30 mm Hg; in 5% the drop was 60 mm Hg. The
frequency of fall in blood pressure increased with age and with
the presence of a number of different neurologic and metabolic
disorders such as advanced atherosclerosis, diabetes, multiple
sclerosis, syringomyelia, syphilitic tabes dorsalis, and peripher-
al neuropathy.
More important than this change in blood pressure on stand-
ing is the frequency of a dramatic difference between intraarte-
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rial blood pressure and the blood pressure observed by the
conventional indirect method. In 1978, Spence, Sibbald, and
Cape measured blood pressure in 24 hypertensive patients 62 to
84 years of age both intraarterially and by the indirect method.
In 12 of the 24, the indirect diastolic pressure was falsely
elevated by 30 mm Hg or more [28]. We compared intraarterial
and indirect measurements in another group of 24 elderly
patients and we found an overestimation in the systolic blood
pressure in 20 and in the diastolic pressure in 12 (Blei A, Pitlick
S, Rosenfeld JB, unpublished observations) (Fig. 1). In 10
younger hypertensive patients, ranging in age from 30 to 55
years, systolic pressure was higher by the indirect method in
only 2; the diastolic pressure was significantly overestimated by
the indirect method in only one (Fig. 2). The "pseudohyperten-
sion" in the elderly group is probably explained by the air-filled
bladder of the sphygmomanometer having difficulty in com-
pressing a stiff brachial artery [29, 30]. One should bear in mind,
therefore, that as many as 80% of patients over age 65 can have
falsely high systolic blood pressures, and as many as 50%
manifest falsely high diastolic pressures. When vigorously
treated, these patients respond poorly and have many side
effects including overt hypotensive episodes.
In addition to the problem caused by overestimation of
intraarterial blood pressure, underestimation of systolic blood
pressure also frequently occurs in the elderly because an
auscultatory gap occurs more often in elderly than in younger
individuals. If the cuff is inflated to higher than 250 mm Hg and
deflated slowly, the true systolic value will not be missed.
Prognosis. A Veterans Administration study found that 25%
of patients over 60 years of age were benefited by treatment for
hypertension [31]. Data from the Hypertension-Stroke Cooper-
ative Study Group failed to reveal decreased mortality or
morbidity in treated elderly patients, however [321. Unfortu-
nately, no controlled prospective studies have been conducted
in isolated and predominant systolic hypertension, probably the
most common form of hypertension in the elderly.
Treatment. The physician treating elderly hypertensive pa-
tients must answer three important questions: (1) At what level
of blood pressure should treatment begin? (2) What are the
benefits of therapy? (3) What are the side effects of treatment?
It is especially important in the elderly that therapy not be
initiated until one has accurately and clearly established a
diagnosis of hypertension. Further, one should assess the
possibility of coexisting diseases, such as an arteriovenous
fistula, thyrotoxicosis, anemia, complete arteriovenous block,
and aortic regurgitation. In patients with clear evidence of end-
organ damage, we treat patients with systolic blood pressures
above 180 mm Hg or diastolic blood pressures above 100 mm
Hg. If no end-organ damage has occurred, we only recommend
general measures, such as reduced salt intake, reduced smok-
ing, and weight reduction [33—35].
If hypertension requires antihypertensive therapy, the physi-
cian should bear in mind that the elderly usually have dimin-
ished renal function. Impairment of renal function is the princi-
pal explanation for the two- to threefold greater incidence of
adverse drug reactions in the elderly as compared to younger
adults [36—38]. In addition, older patients manifest poor compli-
ance with therapeutic regimens, especially when more than one
dose of drug is required daily [39].
Isolated systolic hypertension in the elderly is often resistant
to therapy [40], and aggressive treatment can be hazardous
because a reduction in diastolic pressure can impede the blood
flow to vital organs [41, 42]. The physician should always try to
achieve maximum drug efficacy with a minimum of side effects.
The use of reserpine, clonidine, or methyldopa carries a high
risk of central nervous system side effects. One report, howev-
er, concludes that methyldopa may cause fewer problems than
do the others [43]. Because of reduced baroreceptor reflexes in
the elderly and this group's susceptibility to hypotension,
adrenergic blocking drugs such as guanethidine and bethanidine
should not be used [44]. Because vasodilators are not effective
in our experience [42], we generally choose diuretics or beta-
adrenergic blocking agents. The beta blockers have a high
degree of bioavailability because they undergo limited "first-
pass metabolism"; thus, a high plasma concentration is often
achieved, contributing to the incidence of adverse reactions
associated with the use of these agents in the elderly [36].
Although there is no definitive proof that treatment of hyper-
tension in the elderly improves prognosis [45], an active but
cautious approach is indicated in selected patients. Many areas
require further study, especially the treatment of isolated
systolic hypertension, the efficacy and safety of the various
antihypertensive agents used in the elderly, and the design of a
better therapeutic regimen that will ensure better compliance.
Questions and answers
DR. JORDAN J. COHEN: We are fortunate to have Dr. Gabriel
Richet with us today. Dr. Richet, would you like to comment?
PROF. GABRIEL RICHET (Professor of Nephrology, Hôpital
Tenon, Paris, France): I would like to ask Dr. Rosenfeld
whether he is sure that the patient under discussion today has
essential hypertension. I raise this question because there were
many signs of peripheral vascular disease. He had a bruit in the
left carotid artery and absent pulses in the left lower extremity.
Could he have narrowing of one or both renal arteries? No
difference was noted in size of the kidney but this does not
exclude the possibility.
DR. ROSENFELD: Your point is well taken. One must be very
cognizant about the possibility of renal artery stenosis due to
atheromatous plaque when evaluating a patient with general-
ized atherosclerosis. Because of the negative screening tests,
stable renal function for 6 years and the patient's age, we
decided that we didn't have sufficient reason to risk performing
renal angiography. The point I would like to emphasize, howev-
er, is that this patient's blood pressure, when taken intraarteri-
ally, was compatible with his age alone. We therefore thought
he did not have significant hypertension of any kind.
DR. JACK AGMON (Department of Cardiology, Beilinson
Hospital, Petach Tikva): You argued quite persuasively, Dr.
Rosenfeld, that treating elderly patients with hypertension is
risky because of the numerous complications of treatment and
the absence of definitive proof that such treatment decreases
the incidence of hypertension-induced morbidity and mortality.
It seems to me that you might well have concluded from your
analysis that elderly patients with hypertension should not be
treated at all.
DR. ROSENFELD: I must confess that I don't know what is the
optimal approach in the elderly. A beneficial effect of therapy
was documented in the American Veterans Administration
study [31], but that study only had a small group—about 15%—
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over age 60 and no patients over age 64. So we cannot take
these data as a reasonable basis for deciding about treatment of
the elderly. The authors of the large Chicago study {34j claim
that there is enough evidence to treat all hypertensive pa-
tients—even those in the elderly age group. I personally am not
convinced that the results of that study are clear enough to
permit us to make a final conclusion about the benefits of
treating the elderly hypertensive. Let me reemphasize the
enormity of the problem. In Israel perhaps 50% of people
between 65 and 76 have high blood pressure. To treat this group
adequately would require an enormous expense and I don't
know whether we would be doing much good.
DR. GEOFFREY BONER (Renal Unit, Beilinson Hospital,
Petach Tikva): Professor Richet mentioned the problem of renal
vascular hypertension in the elderly. As he noted, elderly
patients who have atherosclerotic heart disease may also have
plaques in their renal arteries. Is there any evidence in the
elderly that surgical treatment of renal vascular hypertension is
beneficial? A related issue, of course, is whether we should
fully investigate the elderly patient with hypertension before
initiating treatment.
DR. ROSENFELD: Just by looking at the expression on Profes-
sor Richet' s face I can tell you that he does not think that these
patients routinely require full investigation. I am doubtful that
there is much benefit to be derived from corrective surgery at
this age. Do you agree, Professor Richet?
PROFESSOR RICHET: I think that surgical treatment of such
patients is indicated only when there is progressive reduction in
renal blood flow. If renal blood flow is insufficient to sustain
adequate renal function, you might be obliged to interfere
surgically.
PROF. JACK PINKAS (Beilinson Hospital, Petach Tikva): Dr.
Rosenfeld alluded to a vast amount of overtreatment of hyper-
tension that occurs among the elderly. I can't comment about
the situation in the world at large, but I know the problem in
Israelis not just with the physicians. Certainly we must start by
reeducating the physician but we must reeducate the public as
well. I believe the latter may be a mission impossible, especially
for our population of patients. Many seem obsessed with
hypertension. They buy an apparatus to measure and record
their own blood pressure, which many do several times daily.
They often begin treating themselves. If they go to a distin-
guished specialist who tries to suggest that treatment is unnec-
essary, they ignore the advice and seek another consultant until
they find someone who suggests increasing the dosage of their
medication. We must figure out some way to convince the next
generation that more and more medication may not be the best
answer to every problem.
PRoF. ZIGMOND LEVITUS (Beilinson Hospital, Petach
Tikva): The patient we are discussing here was not properly
diagnosed until an intraarterial blood pressure measurement
was performed. Does this suggest that such measurements
should be done routinely in evaluating elderly patients with
hypertension?
DR. ROSENFELD: In our opinion, about 25% of the elderly
who are labeled as hypertensive have what we call pseudohy-
pertension. I think it is much less risky to perform an intraarte-
rial blood pressure determination in such a patient than it is to
treat nonexistent hypertension for several years. The procedure
is simple and virtually painless. We have the patient lie supine
Fig. 3. Pharmacokinetic factors which determine circulating plasma
level of drug and the concentration of drug at its site of action. Since
these pharmacokinetic factors are altered by increasing age, the con-
centration of drug in the biophase of an effector organ is also altered by
increasing age, irrespective of alterations in effector organ sensitivity.
See text for further explanation.
for half an hour in a relaxed atmosphere. Then, in 10 or 15
minutes we take about five readings. We believe it well worth
the mild discomfort and low risk. Certainly patients who appear
to have hypertension but who lack compatible physical findings
such as funduscopic changes, renal damage, or cardiac enlarge-
ment deserve consideration for this bedside procedure.
DR. COHEN: You have made frequent reference to a major
problem that plagues this field—namely, the heterogeneous
nature of hypertension in this age group. Even if we exclude the
important subset of patients with pseudohypertension, we are
still left with several categories to contend with. This makes it
difficult, of course, to assess reports that fail to stratify patients
in a consistent way. In this connection, I would like to ask you
about those relatively few elderly patients with significant
diastolic hypertension. Accepting the clinical maxim that the
onset of essential hypertension after the age of 50 or 55 is rare,
do you think it important to distinguish between those in whom
essential hypertension simply went undetected until an ad-
vanced age and those in whom a "secondary" form of hyper-
tension is present?
Da. ROSENFELD: I think elderly patients with clear-cut
diastolic hypertension should be viewed much the way we view
younger patients with this form of hypertension.
Forum commentary
DR. JAY ROBERTS (Professor and Chairman, Department of
Pharmacology, The Medical College of Pennsylvania, Philadel-
phia, Pennsylvania): In discussing the use of any drug in any
age group, one must clearly define pharmacokinetics, pharma-
codynaniics, side effects, and toxicity. Pharmocokinetics in-
volves the processes determining the concentration of a drug at
its site of action. "Pharmacodynamics" refers to those process-
es influencing the effects of a drug on an end organ. "Side
effects" refers to undesired actions of a drug that stem from its
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Clonidine
Digitoxin
Digoxin
Guanethidine
Hydralazine
Methyldopa
Reserpine/rauwolfia
Thiazide diuretics
No change in dose
Decrease dose
No change in dose
Unknown
95% metabolized in the liver. Monitor for
signs of liver damage or toxicity
Do not use in patients with end-stage disease
No change in dose
Use with caution
Use with caution
No change in dose
Decrease dose
Decrease dose
Administer twice daily at most
Reduce dose
No change in dose
Use with caution
a Modified from ref. 55.
principal pharmacologic action. For example, orthostatic hypo-
tension is a side effect of certain antihypertensive agents
because, in the process of lowering blood pressure, these agents
also inhibit cardiovascular reflexes important in maintaining
blood pressure in the upright posture. "Toxicity" refers to
undesirable responses to a drug that are not related to the
agent's principal pharmacologic action. For example, the lupus-
like syndrome produced by prolonged administration of pro-
cainamide is a toxic manifestation of this antiarrhythmic agent.
The relationship between pharmacokinetics, pharmacodynam-
ics, side effects, and toxicity of a drug is shown in Figure 3.
Each of these parameters changes with age. For example,
absorption of drug from the gastrointestinal tract can change as
a function of age because of the increasing prevalence of
achlorhydria [46]; both basal and stimulated gastric acid secre-
tion are known to decrease with age [47]. It therefore would be
expected that the degree of ionization, as well as solubility and
absorption characteristics of various substances, might change
with age. Furthermore, the decrease in blood flow to the
gastrointestinal tract that occurs with age may cause a delay in
the absorption of substances from the intestinal tract. These
and other factors would have the overall effect of making the
absorption of drugs from the gastrointestinal tract a less effi-
cient process as aging occurs.
The effect of age on drug metabolism by liver microsomal
enzyme systems has been studied intensively, especially in
relation to drugs that produce central nervous system effects.
Data indicate that the hepatic metabolism of phenylbutazone
[48], warfarin [49], amobarbital [50], and propranolol [511 is
altered with age. In general, the hall-lives of these agents are
prolonged. Impaired hepatic metabolism seems to play a role in
the prolonged hall-life of the active metabolite of lidocaine in
the aged [52]. Antipyrine, commonly used as a test substance to
elucidate the function of the mixed oxidative enzyme system of
the liver, is metabolized more slowly in the elderly [53]. The
influence of impaired liver function on the use of commonly
used antihypertensive agents is shown in Table 1.
As noted by Dr. Rosenfeld, reduced renal function with
increasing age is the consequence of changes in renal hemody-
namics as well as in the nephrons themselves. The overall effect
of this age-related decline in renal function is, of course, less
efficient clearance of water-soluble drugs, and therefore for a
given dose, higher circulating drug levels in older patients. It
follows that dosage schedules must be adjusted accordingly.
Drugs excreted by the kidney for which significant age-related
changes have been documented include penicillin, dihydro-
streptomycin, tetracycline, kanamycin, digoxin, and phenobar-
bital [541. An extensive list of drugs whose elimination is
influenced by reduced kidney function is given by Lamy [551.
Antihypertensive drugs affected by altered kidney function are
listed in Table 1.
As pointed out by Goldberg and Roberts [56, 57] and by
Vestal [54], more attention should be given to the possibility
that age-related changes in the effector organ can alter the
response to drugs. The effect of increasing age, especially from
adulthood to old age, is generally associated with reduced
tolerance to drugs [54, 58, 59]. This effect appears to be due
primarily to a diminished functional capacity of many organ
systems. As an example of such reduced tolerance, older
patients are especially sensitive to the antihypertensive and the
central nervous system depressant effects of methyldopa and
other agents with similar properties [60]. Reserpine is even
more of a problem, and its use should be discouraged.
Postural hypotension is common in the elderly, largely be-
cause of an impaired baroreceptor response [61] and a reduction
in peripheral venous tone [62]. As noted by Dr. Rosenfeld,
severe orthostasis and syncope often obviate the use of antihy-
pertensive medications in elderly patients; at the very least,
concern about these complications requires that the dose of the
antihypertensive agent be titrated even more cautiously than in
younger patients.
Advancing age also is associated with a diminished cardiac
and vascular response to catecholamines. Both the chronotro-
pic and the inotropic responses of the heart to adrenergic
substances diminish with age [63]. Receptor-binding studies
using radioligand methods indicate that neither the density of
receptors nor their affinity for catecholamines diminishes with
age [64, 651. Thus it will be necessary to explore other sites
along the pathway triggered by beta-receptor agonists to deter-
mine the nature of the decreased response. The importance of
studies of this nature has recently been reviewed by Lakatta
[66].
Increasing age also has a profound effect on the response of
the vasculature to autonomic agents. Aging reduces the ability
of isoproterenol to induce relaxation of the aorta [671. Aortas
obtained from older rats also exhibit a decreased relaxation
response to norepinephrine [68, 691. These studies suggest that
the age-related defect in relaxation lies somewhere along the
beta-adrenergic receptor-response system. The relaxation
mechanism itself remains intact, however, because its response
to the nonspecific agent, nitrate, was undiminished [67].
The linkage between the central nervous system and vascular
Table 1. Implications of impaired liver and renal function on the use ofcertain drugsa
Drug Impaired liver function Impaired kidney function
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smooth muscle is complex, and sites other than the drug
receptor itself could exhibit age-dependent changes that might
affect drug action. For example, differences between old and
young rabbits have been found in adrenergic innervation of the
vascular smooth muscle [70]. Catecholamine was detected by
specific fluorescence testing in the media of vessels obtained
from young animals, whereas catecholamine was found only in
the adventitia and adventitia-media junction in old animals. The
young rabbits also had levels of tissue catecholamines twice as
high as did the old. The findings were attributed to degeneration
in the adrenergic innervation of the media. Similar findings have
been reported for cardiac tissue obtained from rats; in these
studies, an age-associated degeneration of adrenergic nerve
terminals was apparent in the atrium; this change could account
for the diminished adrenergic control exhibited by the senes-
cent heart [711.
A decrease in the number of nerve terminals might explain a
decrease in the response to adrenergic neural stimulation in
vivo, but it would not explain the decreased pharmacologic
responsiveness to catecholamines described above; as a rule,
denervation leads to an increased responsiveness to the rele-
vant hormones. Perhaps, as Weiss, Greenberg, and Cantor
have concluded from studies of the pineal gland [721, denerva-
tion does not lead to enhanced sensitivity to adrenergic stimuli
in many tissues of older animals.
In summary, it is clear that antihypertensive drug therapy in
the elderly requires special attention because pharmacokinetic,
physiologic, pathologic, and pharmacodynamic parameters are
not only altered in the aged, but also because these alterations
exert a profound influence on the efficacy, side effects, and
toxicity of antihypertensive agents in older patients.
Reprint requests to Prof. J. Rosenfeld, Renal Unit, Beilinson Medical
Center, Petach Tikva, Israel
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